Exchange: NYSE·Updated 07:36 PM EDT
News
all
press releases
Qiagen Breaks Above 200-Day Moving Average - Bullish for QGEN
In trading on Monday, shares of Qiagen NV (Symbol: QGEN) crossed above their 200 day moving average of $42.98, changing hands as high as $44.41 per share. Qiagen NV shares are currently trading up about 3.6% on the day. The chart below shows the one year performance of QGEN sh...
Nasdaq News: Markets
More News
QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance. The clearance expands QIAGENs U.S. syndromic...
Business Wire
Understanding Qiagen (QGEN) Reliance on International Revenue
Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Zacks
Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of +3.33% and +1.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Qiagen (QGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks
QIAGEN Q2 Profit Rises
(RTTNews) - QIAGEN N.V. (QGEN) on Wednesday reported higher second-quarter earnings, while the molecular diagnostics company reaffirmed its full-year 2026 outlook...
Nasdaq News: Markets
QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for Q2 2026, with net sales and adjusted diluted earnings per share exceeding the outlook while maintaining a high level of profitability. Net sales for Q2 2026 were unchanged at $535 million on a reported basis and at...
Business Wire
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis cases reported across the United States. More than 1,600 U.S. cases of cyclosporiasis have been...
Business Wire

Advertisement|Remove ads.